Michael H. Weisman
Cedars-Sinai Health System
Los Angeles
California 90048
USA
Name/email consistency: high
- Development and validation of a case ascertainment tool for ankylosing spondylitis. Weisman, M.H., Chen, L., Clegg, D.O., Davis, J.C., Dubois, R.W., Prete, P.E., Savage, L.M., Schafer, L., Suarez-Almazor, M.E., Yu, H.T., Reveille, J.D. Arthritis. Care. Res. (Hoboken) (2010)
- Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. Weisman, M.H., Durez, P., Hallegua, D., Aranda, R., Becker, J.C., Nuamah, I., Vratsanos, G., Zhou, Y., Moreland, L.W. J. Rheumatol. (2006)
- Development of a new instrument for rheumatoid arthritis: the Cedars-Sinai Health-Related Quality of Life instrument (CSHQ-RA). Weisman, M.H., Paulus, H.E., Russak, S.M., Lubeck, D.P., Chiou, C.F., Sengupta, N., Ofman, J.J., Borenstein, J., Moadel, A.B., Sherbourne, C.D., Paulus, H.D. Arthritis Rheum. (2003)
- Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Weisman, M.H., Moreland, L.W., Furst, D.E., Weinblatt, M.E., Keystone, E.C., Paulus, H.E., Teoh, L.S., Velagapudi, R.B., Noertersheuser, P.A., Granneman, G.R., Fischkoff, S.A., Chartash, E.K. Clin. Ther (2003)
- Newly diagnosed rheumatoid arthritis. Weisman, M.H. Ann. Rheum. Dis. (2002)
- What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. Weisman, M.H. J. Rheumatol. Suppl (2002)